Phase 3 ARCHER II Enrollment Complete; Topline Data Due Q4 2026
ANNX has more than doubled off its 52-week low of $2.03.
Summary
Annexon completed enrollment of 659 patients in the pivotal Phase 3 ARCHER II trial for vonaprument, a C1q inhibitor, with topline results expected in Q4 2026. This follows the recent ASRS presentation of Phase 2 baseline characteristics and keeps the program on track for a potential regulatory filing. The company also granted 335,000 inducement options to two new hires at a $6.50 strike, a modest equity award. With a market cap near $950M and cash runway into H2 2027, the ARCHER II readout is the next major binary event for the stock.
At the time of this announcement, ANNX was trading at $5.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $950.3M. The 52-week trading range was $2.03 to $7.18. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.